Codexis Inc(CDXS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:20 PM ET (Korea 10/30 05:20)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.34 | Insider Own | 7.1% | Shs Outstand | 109.5M | Perf Week | -7.63% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 26.36% | Insider Trans | -0.2% | Shs Float | 101.7M | Perf Month | -12.95% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.1 | Inst Own | 62.35% | Short Float | 4.87% | Perf Quarter | -13.57% |
| Income | -0.03B | P/S | 1.71 | EPS this Y | 24.86% | Inst Trans | -3.25% | Short Ratio | 5.28 | Perf Half Y | -57.09% |
| Sales | 0.08B | P/B | 3.36 | EPS next 5Y | 39.03% | ROA | -23.79% | Short Interest | 4.95M | Perf YTD | -25.77% |
| Book/sh | 0.36 | P/C | 2.39 | EPS past 3/5Y | 0.62% -4.52% | ROE | -69.36% | 52W High | -59.4% ($2.98) | Perf Year | -50% |
| Cash/sh | 0.51 | P/FCF | - | Sales past 3/5Y | -20.22% 0.38% | ROIC | -32.27% | 52W Low | 26.27% ($0.96) | Perf 3Y | -21.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 58.7% | Gross Margin | 80.47% | Volatility(W/M) | 3.88% 6.28% | Perf 5Y | -96.52% |
| Dividend TTM | - | EV/Sales | 1.93 | Sales Y/Y TTM | 35.89% | Oper. Margin | -31.23% | ATR (14) | 0.08 | Perf 10Y | -73.11% |
| Dividend Ex-Date | - | Quick Ratio | 2.99 | EPS Q/Q | 15.19% | Profit Margin | -39.55% | RSI (14) | 39.05 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.06 | Sales Q/Q | -2.69% | SMA20 | -8.3% ($1.32) | Beta | 2.37 | Target Price | $6.14 |
| Payout | - | Debt/Eq | 2.2 | Earnings | 2026/8/11 | SMA50 | -14.07% ($1.41) | Rel Volume | 0.97 | Prev Close | $1.26 |
| Employees | 146 | LT Debt/Eq | 1.89 | EPS/Sales Surpr. | 8.26% 7.89% | SMA200 | -33.53% ($1.82) | Avg Volume(3M) | 0.94M | Price | $1.21 |
| IPO | 2010/4/22 | Option/Short | Yes/Yes | Trades | 2817 | Volume | 913,854 | Change | -3.97% |
🧬 Codexis (CDXS) is a US biotech company based on protein engineering that artificially evolves enzyme proteins. Using its proprietary directed evolution platform, it designs custom enzymes used in pharmaceutical synthesis and gene therapeutics manufacturing, and has recently shifted its business focus to the ECO Synthesis platform for nucleic acid and oligonucleotide manufacturing.
Over the past 1 year, on the lower side
59% below its 1-year high.
Traded about as much as usual. That is 97% of its average volume.
CDXS has a sound balance sheet but weak earning power
Of every $100 in sales, $31.23 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $171. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 62.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #336 of 594 in the industry
Based on market cap of $133M.
FAQ
What kind of company is CDXS?
CDXS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CDXS?
The market cap of CDXS is approximately $133M, ranking 4,321 within its sector.
What is the 52-week high and low for CDXS?
CDXS has recorded a 52-week high of $2.98 and a low of $0.96.
